Ratings by Rodman & Renshaw (Seema Sheoran)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/21/2026 | Eledon Pharamceuticals | ELDN | New Coverage | Buy (N/A) |
3.86 (2.82) |
-26.94% | Details | |
| 6/3/2026 | Neurogene | NGNE | New Coverage | Buy (N/A) |
26.14 (37.88) |
44.91% | Details | |
| 4/14/2026 | CAMP4 Therapeutics Corp | CAMP | New Coverage | Buy (N/A) |
4.64 (4.33) |
-6.68% | Details | |
| 4/2/2026 | SAB Biotherapeutics | SABS | New Coverage | Buy (N/A) |
3.87 (3.48) |
-10.08% | Details | |
| 3/26/2026 | Enanta Pharmaceuticals | ENTA | New Coverage | Buy (N/A) |
12.17 (13.24) |
8.79% | Details | |
| 3/26/2026 | Sagimet Biosciences Inc | SGMT | New Coverage | Buy (N/A) |
4.62 (10.86) |
135.06% | Details |
